TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28667678

Group type: EXPERIMENTAL
Intervention: SRP + PDT
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study: 27107668

Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and interpersonal psychotherapy adapted to BPD (IPT-BPD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Single fluoxetine administered for 32 weeks
Number of subjects: 44
Study: 23722581

Group type: EXPERIMENTAL
Intervention: PRINEO™ Skin Closure System
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intradermal sutures
Number of subjects: 79
Study: 22516178

Group type: EXPERIMENTAL
Intervention: Fleet enema
Number of subjects: 130

Group type: COMPARATOR
Intervention: No preoperative intestinal preparation (Control)
Number of subjects: 130
Study: 20117503

Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair (EVAR)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 160
Study: 17443678

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin 1 mg/kg per day) and antithrombin (AT) supplementation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Antithrombin (AT) alone
Number of subjects: 112
Study: 15660024

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: All doses of atorvastatin
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Higher starting doses of atorvastatin
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Atorvastatin (all doses)
Number of subjects: 919
Study: 11844644

Group type: EXPERIMENTAL
Intervention: MCT/LCT
Number of subjects: 72

Group type: COMPARATOR
Intervention: LCT
Number of subjects: 72
Study: 10077372

Group type: EXPERIMENTAL
Intervention: Disposable paper drape system
Number of subjects: 505

Group type: COMPARATOR
Intervention: Reusable fabric drapes
Number of subjects: 505
Study: 8644481

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: proglumide 1600 mg
Number of subjects: 106
Study: 2042093

Group type: EXPERIMENTAL
Intervention: Drainage group (high-pressure suction drain in Morison's pouch for 48 hours)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Nondrainage group
Number of subjects: 479
Study: 6987705

Group type: EXPERIMENTAL
Intervention: Protamine sulfate administration post-procedural
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 31557280

Group type: EXPERIMENTAL
Intervention: HK ratio (HKr)
Number of subjects: 11178

Group type: EXPERIMENTAL
Intervention: PLP and HKr
Number of subjects: 11178
Study: 31103829

Group type: EXPERIMENTAL
Intervention: Smartphone access during examination
Number of subjects: 30

Group type: COMPARATOR
Intervention: No smartphone access during examination
Number of subjects: 30
Study: 26781645

Group type: EXPERIMENTAL
Intervention: Inhalational Ciclesonide (CIC) 640 mcg via metered-dose inhaler at admission and 24 hours later
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no prophylactic therapy)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Inhalational Ciclesonide (CIC)
Number of subjects: 70
Study: 26422097

Group type: EXPERIMENTAL
Intervention: Esomeprazole (2.5-10 mg once daily for 2 weeks, then weight-adjusted doses for 4 weeks)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Esomeprazole (in posthoc analysis)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (in posthoc analysis)
Number of subjects: 98
Study: 23312760

Group type: EXPERIMENTAL
Intervention: Low lutein (LL; 10 mg/d)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High lutein (HL; 20 mg/d)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Lutein plus zeaxanthin (LZ; each 10 mg/d)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 21177661

Group type: EXPERIMENTAL
Intervention: Participatory ergonomics
Number of subjects: 3047

Group type: COMPARATOR
Intervention: Control (no participatory ergonomics)
Number of subjects: 3047
Study: 19342754

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (100 microg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Verapamil (1 mg)
Number of subjects: 20
Study: 17711714

Group type: EXPERIMENTAL
Intervention: CYP1A1 MspI polymorphism in smokers (CC genotype)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: CYP1A1 MspI polymorphism in low dose cigarette smoking group (CC and TC genotypes)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: CYP1A1 MspI polymorphism in high dose cigarette smoking group
Number of subjects: 349
Study: 15285783

Group type: EXPERIMENTAL
Intervention: Pain self-management training group intervention
Number of subjects: 273

Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 273
Study: 11473840

Group type: EXPERIMENTAL
Intervention: 10 mL of 1% lidocaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: 10 mL of 0.9% saline
Number of subjects: 48
Study: 9517603

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conservative Therapy (CT)
Number of subjects: 111
Study: 7996367

Group type: EXPERIMENTAL
Intervention: IVIG (500 mg/kg)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Albumin (5 mg/kg)
Number of subjects: 753
Study: 1971670

Group type: EXPERIMENTAL
Intervention: Pranayama breathing exercises using Pink City lung (PCL) exerciser
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 18
Study: 525751

Group type: EXPERIMENTAL
Intervention: Pyritinol 600 mg infused immediately after anaesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 31889231

Group type: EXPERIMENTAL
Intervention: migalastat (150 mg every other day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: ERT (agalsidase alfa 0.2 mg/kg or agalsidase beta 1.0 mg/kg)
Number of subjects: 7
Study: 30925197

Group type: EXPERIMENTAL
Intervention: Morning fasting (0 kcal until 12:00 pm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily breakfast (> 700 kcal by 11:00 am)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 27077263

Group type: EXPERIMENTAL
Intervention: ULF-TENS applied for 20 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ULF-TENS applied for 40 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ULF-TENS applied for 60 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: ULF-TENS applied for 20 to 40 minutes
Number of subjects: 20
Study: 25766731

Group type: EXPERIMENTAL
Intervention: Family-assisted MI intervention
Number of subjects: 159

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 159
Study: 24145042

Group type: EXPERIMENTAL
Intervention: Clostridial collagenase ointment (CCO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline moistened gauze (SMG)
Number of subjects: 48
Study: 21343172

Group type: EXPERIMENTAL
Intervention: novel endoscopic lens cleaning device
Number of subjects: 40

Group type: COMPARATOR
Intervention: control group
Number of subjects: 40
Study: 19651562

Group type: EXPERIMENTAL
Intervention: NB‐UVB phototherapy 3 times a week for 24 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus 1% cream b.i.d. for 24 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment b.i.d. for 24 weeks
Number of subjects: 44
Study: 17149529

Group type: EXPERIMENTAL
Intervention: Alcohol Dependence Scale (ADS)
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: ADS subscales reflecting psychoperceptual or psychophysical withdrawal
Number of subjects: 1372
Study: 15111848

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - 40 mg of enoxaparin
Number of subjects: 849

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) - 5000 IU heparin
Number of subjects: 849
Study: 11569894

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9588369

Group type: EXPERIMENTAL
Intervention: Low airloss hydrotherapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 116
Study: 8148303

Group type: COMPARATOR
Intervention: Single injection of 20 mL of an amide‐ester solution (1% lidocaine/0.2% tetracaine) with epinephrine 1:200,000
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Double injection of two 10 mL injections of the same solution
Number of subjects: 50
Study: 2900659

Group type: EXPERIMENTAL
Intervention: Steroids for at least 18 months
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Plasma exchange and prednisone
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Cytotoxic agents (27% of patients)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Age over 50, gastrointestinal problems, cardiomyopathy, renal signs
Number of subjects: 165
Study: 31315670

Group type: EXPERIMENTAL
Intervention: bilateral erector spinae block (20 mL 0.25% levobupivacaine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: bilateral sham block (20 mL NaCl 0.9%)
Number of subjects: 80
Study: 28322776

Group type: EXPERIMENTAL
Intervention: 250 mL/h of normal saline
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 125 mL/h of 5% dextrose in normal saline
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 250 mL/h of 2.5% dextrose in normal saline
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (250 mL/h of normal saline)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (125 mL/h of 5% dextrose in normal saline)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (250 mL/h of 2.5% dextrose in normal saline)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 274
Study: 26016162

Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy with Ir‐192
Number of subjects: 105

Group type: COMPARATOR
Intervention: Radical prostatectomy followed by adjuvant remote radiotherapy
Number of subjects: 105
Study: 24174945

Group type: EXPERIMENTAL
Intervention: Septal injection of 40 U of BTA (Dysport(®), Ipsen Ltd)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Turbinal injection of 40 U of BTA (Dysport(®), Ipsen Ltd)
Number of subjects: 50
Study: 21696934

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FSC) 250/50 μg twice-daily
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 19929596

Group type: EXPERIMENTAL
Intervention: Intracameral bevacizumab injection at a concentration of 1.25 mg/0.05 mL
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intracameral bevacizumab injection
Number of subjects: 10
Study: 18200772

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Co-amilozide (amiloride plus hydrochlorothiazide)
Number of subjects: 0
Study: 15116815

Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation with continuous epidural analgesia, enforced oral nutrition, mobilisation, planned early discharge
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation
Number of subjects: 30
Study: 10757250

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9380353

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8404935

Group type: EXPERIMENTAL
Intervention: Streptokinase initiated 12-49 hours after onset of symptoms, followed by heparin for at least 5 days and warfarin and dipyridamole for at least 3 months
Number of subjects: 111

Group type: COMPARATOR
Intervention: Routine treatment without any of these drugs
Number of subjects: 111
Study: 3950112

Group type: EXPERIMENTAL
Intervention: 1% indomethacin cream
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1% meclofenamate cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle therapy
Number of subjects: 30
Study: 30374890

Group type: COMPARATOR
Intervention: Remifentanil 12 ng/ml (Group 5)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: All groups (including Group 1: 0 ng/ml, Group 2: 2 ng/ml, Group 3: 4 ng/ml, Group 4: 8 ng/ml, Group 5: 12 ng/ml)
Number of subjects: 198
Study: 26762908

Group type: EXPERIMENTAL
Intervention: Newer-generation drug-eluting stents (DES)
Number of subjects: 4217

Group type: COMPARATOR
Intervention: Older-generation drug-eluting stents (DES)
Number of subjects: 4217

Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) <45 ml/min
Number of subjects: 4217

Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) 45 to 59 ml/min
Number of subjects: 4217

Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) ≥60 ml/min
Number of subjects: 4217
Study: 24332588

Group type: EXPERIMENTAL
Intervention: Ozone therapy on the study side
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham ozone therapy on the control side
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 60
Study: 22616058

Group type: EXPERIMENTAL
Intervention: Materialise SimPlant
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nobel Biocare
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bone-supported guides
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: All provisionals
Number of subjects: 14
Study: 20339731

Group type: EXPERIMENTAL
Intervention: Motivational interviewing + thought mapping + cognitive-behavioral group therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cognitive-behavioral group therapy
Number of subjects: 40
Study: 18503905

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 201

Group type: COMPARATOR
Intervention: Empathic Attention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 201
Study: 15935383

Group type: EXPERIMENTAL
Intervention: Rifampin (300 mg twice daily) and Azithromycin (500 mg every other day) for 6 months
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 8
Study: 12575975

Group type: EXPERIMENTAL
Intervention: Tc‐99m sestamibi injected during last balloon inflation (acute MPI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tc‐99m sestamibi injected at 15 min following balloon deflation (delayed MPI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tc‐99m sestamibi injected at 1, 2, or 3 h (delayed MPI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tc‐99m sestamibi injected at 24 to 48 h (late MPI)
Number of subjects: 40
Study: 10556995

Group type: EXPERIMENTAL
Intervention: Extruded blended flour (EF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-extruded blended flour (NEF)
Number of subjects: 8
Study: 8701885

Group type: EXPERIMENTAL
Intervention: Wiktor stent implantation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty
Number of subjects: 84
Study: 1895045

Group type: EXPERIMENTAL
Intervention: Early intravenous metoprolol followed by oral treatment for 15 days
Number of subjects: 5778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5778
Study: 6340971

Group type: EXPERIMENTAL
Intervention: Oxaprozin 1200 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sulindac 200 mg twice daily
Number of subjects: 20
Study: 30999762

Group type: EXPERIMENTAL
Intervention: Matching product attributes
Number of subjects: 20000
Study: 29248173

Group type: EXPERIMENTAL
Intervention: Tube shunt (350‐mm2 Baerveldt glaucoma implant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (0.4 mg/ml for 2 minutes)
Number of subjects: 0
Study: 26611525

Group type: EXPERIMENTAL
Intervention: 0.9% NaCl+ambroxol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.45% NaCl
Number of subjects: 30
Study: 25075828

Group type: EXPERIMENTAL
Intervention: Cases (CVTs who reported work-related bite injuries)
Number of subjects: 868

Group type: COMPARATOR
Intervention: Controls (CVTs who did not report work-related bite injuries)
Number of subjects: 868
Study: 21948120

Group type: EXPERIMENTAL
Intervention: Exercise group (EG, n=40)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (CG, n=43)
Number of subjects: 83
Study: 18988860

Group type: EXPERIMENTAL
Intervention: History of moderate to severe childhood abuse
Number of subjects: 0
Study: 17553394

Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 351

Group type: COMPARATOR
Intervention: Day hospital visits
Number of subjects: 351
Study: 15219654

Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone treatment (2 doses of 12 mg administered intramuscularly to the mother twelve hours apart)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No antenatal betamethasone treatment
Number of subjects: 18
Study: 12234700

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Cisplatin and VP-16 administered concurrently with radiotherapy (CRT)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Overall survival comparison between genders
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Non-squamous histology tumors in women
Number of subjects: 488
Study: 9664953

Group type: EXPERIMENTAL
Intervention: CsA‐ME (cyclosporine microemulsion)
Number of subjects: 31

Group type: COMPARATOR
Intervention: CsA (original formulation of cyclosporine)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CsA‐ME
Number of subjects: 31
Study: 8583176

Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0
Study: 2803892

Group type: EXPERIMENTAL
Intervention: Ephedrine 12.5 mg i.v. and 37.5 mg i.m.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31722150

Group type: EXPERIMENTAL
Intervention: MVA
Number of subjects: 440

Group type: COMPARATOR
Intervention: ACAM2000
Number of subjects: 440
Study: 27863315

Group type: EXPERIMENTAL
Intervention: Active tDCS (2mA/20min/day for 5 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 17
Study: 26666523

Group type: EXPERIMENTAL
Intervention: Breathing into the snow with a one-liter air pocket (AP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Breathing into the snow with no air pocket (NP)
Number of subjects: 10
Study: 23073706

Group type: EXPERIMENTAL
Intervention: MIS anterolateral approach
Number of subjects: 156

Group type: COMPARATOR
Intervention: Surgeon's preferred approach (direct lateral or posterolateral)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: MIS anterolateral group
Number of subjects: 156
Study: 21640214

Group type: EXPERIMENTAL
Intervention: Weight Bearing Exercises Program (WBEP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Traditional Exercises Program (TEP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 45
Study: 19274409

Group type: EXPERIMENTAL
Intervention: World Vision Disposable Asférica Wave Front
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acuvue 2
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both soft contact lenses
Number of subjects: 40
Study: 16584949

Group type: EXPERIMENTAL
Intervention: Hands-on therapy including heat, massage, and active exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: Education with active exercises
Number of subjects: 24
Study: 15541838

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning during coronary angioplasty
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 36
Study: 11382647

Group type: EXPERIMENTAL
Intervention: Daily disposable contact lenses
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Disposable extended wear contact lenses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 50
Study: 9238873

Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride dentifrice (Crest Plus Gum Care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice (Mentadent) and essential oil mouthrinse (Listerine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baking soda and peroxide (NaF) dentifrice (Mentadent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse (Listerine) and stabilized stannous fluoride dentifrice (Crest Plus Gum Care)
Number of subjects: 0
Study: 7952800

Group type: EXPERIMENTAL
Intervention: Propafenone administered as a slow release formulation at 2 x 225 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Propafenone administered as a slow release formulation at 2 x 325 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Propafenone administered as a slow release formulation at 2 x 425 mg
Number of subjects: 86
Study: 3306493

Group type: EXPERIMENTAL
Intervention: 1.5 g of elemental calcium per day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 29017908

Group type: EXPERIMENTAL
Intervention: RD 7 bananas (more ripened, visually suboptimal)
Number of subjects: 233

Group type: COMPARATOR
Intervention: RD 5 bananas (control)
Number of subjects: 233
Study: 27561923

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 25637395

Group type: EXPERIMENTAL
Intervention: Wheat muffins
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rice muffins
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Corn muffins
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oat muffins
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Barley muffins
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wholegrain muffins (excluding corn)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference glucose solution
Number of subjects: 12